Quarterly Results


1Q 2023

First Quarter 2023 Highlights
  • Net income of $0.22 per share, Nareit FFO of $0.42 per share, FFO as Adjusted of $0.42 per share, AFFO of $0.38 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 5.5%
    • Life Science and MOB Same-Store Portfolio Cash (Adjusted) NOI growth of 6.3% and 3.7%, respectively
  • First quarter life science new and renewal lease executions totaled 311,000 square feet, with +55% cash releasing spreads on renewals
  • Placed-in-service the remaining 19,000 square feet at 101 CambridgePark Drive
  • Balance Sheet:
    • In January 2023, issued $400 million of 5.25% fixed rate 10-year senior unsecured notes
    • Net debt to Adjusted EBITDAre was 5.4x as of March 31, 2023
  • On February 10, 2023, Healthpeak implemented a holding company reorganization to an Umbrella Partnership Real Estate Investment Trust (UPREIT)
  • Board of Directors: 
    • Kathy Sandstrom appointed Chair of the Board of Directors
    • Jim Connor appointed as an independent director
  • Healthpeak's Board of Directors declared today a quarterly common stock cash dividend of $0.30 per share to be paid on May 19, 2023, to stockholders of record as of the close of business on May 8, 2023 
  • Recent ESG accomplishments include:
    • Earned the 2023 ENERGY STAR® Partner of the Year Award from the U.S. Environmental Protection Agency and the U.S. Department of Energy, marking Healthpeak's third time receiving the award
    • Ranked in the top 10% of companies by ISS for each of our environmental, social, and governance quality scores
    • Named a Women's Forum of New York Corporate Champion for the fifth time